OPERS Federal Comment Letters
OPERS has a significant interest in the regulatory process at the federal level.
Staff actively comment and participate in the development of federal regulations specifically in health care, investments, and corporate governance.
Below are comment letters submitted by OPERS to various agencies such as the FDA, CMS, IRS, and HHS.
- OPERS Comment Letter – Treasury, Labor, and Health and Human Services – HRA Access and Usabilitylink opens in new tab
(Dec. 27, 2018) - OPERS comment letter to the FDA: Facilitating Competition and Innovation in the Biological Products Marketplacelink opens in new tab
(Sept. 21, 2018) - OPERS Comment Letter - American Patients Firstlink opens in new tab
(July 16, 2018) - OPERS Comment Letter - FDA – Oncologic Drugs Advisory Committeelink opens in new tab
(May 3, 2017) - OPERS Comment Letter to the FDA - Biosimilar Interchangeabilitylink opens in new tab
(March 10, 2017) - Letter of Support for PRICED Act Biosimilars Billlink opens in new tab
(Sept. 26, 2016) - Public Sector Health Care Roundtable Letter Regarding Increased Medicare Part B Premiumslink opens in new tab
(Sept. 27, 2016) - OPERS Comment Letter to the Centers for Medicare and Medicaid Services (CMS) - Expansion of the Medicare Diabetes Prevention Program (DPP)link opens in new tab
(Sept. 6, 2016) - OPERS Comment Letter - FDA - Arthritis Advisory Committeelink opens in new tab
(June 28, 2016) - OPERS Comment Letter - FDA - Biosimilar Labelinglink opens in new tab
(June 1, 2016) - Public Sector Healthcare Roundtable Comment letter to U.S. HHS re: Medicare Part-B link opens in new tab
(May 6, 2016) - OPERS letter in support of Celltrion's Biologics License Application for a biosimilar infliximablink opens in new tab
(Feb. 3, 2016) - OPERS Testifies to US House Democratic Steering and Policy Committeelink opens in new tab
(Nov. 30, 2015) - Letter of support to U.S. Senate re: FAST Generics Actlink opens in new tab
(Dec. 21, 2015) - Biosimilars Network Letter to FDA re: Biosimilars Naming Guidancelink opens in new tab
(Nov. 3, 2015) - OPERS Comment Letter to FDA on biologics naminglink opens in new tab
(Oct. 27, 2015) - OPERS Comment Letter to John Boehner on projected Medicare Part B Premium Increaseslink opens in new tab
(Oct. 1, 2015) - Joint Letter to Legislators on projected Medicare Part B Premium Increaseslink opens in new tab
(Sept. 30, 2015) - OPERS Comment Letter to HHS on Medicare program; revisions to payment policieslink opens in new tab
(Sept. 8, 2015) - OPERS Comment Letter to HHS on Medicare program; revisions to payment policieslink opens in new tab
(Sept. 8, 2015) - OPERS Comment Letter – Additional Q&A Regarding Implementation of BPCIAlink opens in new tab
(July 9, 2015) - Biosimilars Network Letter to FDA re: Biosimilars Naminglink opens in new tab
(June 30, 2015) - Letter of Support re: FAST Generics Act of 2015link opens in new tab
(June 17, 2015) - Letter to IRS on Excise Tax on High Cost Employer-Sponsored Health Coveragelink opens in new tab
(May 15, 2015) - Letter to U.S. House of Representatives Energy & Commerce Committee re: 21st Century Cures Initiativelink opens in new tab
(May 8, 2015) - Letter to FDA on Labelinglink opens in new tab
(April 27, 2015) - Biosimilar – Burwell letterlink opens in new tab
(April 27, 2015) - Comments to the FDA on Risk Evaluation and Mitigation Strategy programs
link opens in new tab
(January 26, 2015)
Below are comment letters submitted by OPERS to various agencies such as the SEC, FTC, IRS, and Treasury.
- OPERS Comment Letter - FDA – Oncologic Drugs Advisory Committeelink opens in new tab
(May 3, 2017) - Comment on Proposed Listing Standards for Recovery of Erroneously Awarded
Compensationlink opens in new tab
(Sept. 14, 2015) - Comment on Proposed Pay versus Performance Disclosure Rulelink opens in new tab
(July 6, 2015)